Related Experiment Video
Updated: Feb 3, 2026

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Breast Implant-Associated Lymphoma.
Julian Kricheldorff1, Eva Maria Fallenberg, Christine Solbach
1Department of Plastic and Esthetic Surgery, Hand Surgery, Helios Hospital Emil von Behring, Berlin; Department of Radiology, Mammography Section, Charité University Medicine Berlin, Virchow Hospital Campus; Breast Center, Department of Gynecology and Obstetrics, University Hospital Frankfurt; Vivantes Breast Center, Am Urban Hospital, Berlin; Institute for Tissue Diagnostics Berlin Medical Center, Helios Hospital Emil von Behring, Berlin; Department of Plastic and Esthetic Surgery, Hand Surgery, Helios Hospital Emil von Behring, Berlin.
Breast implants are rarely linked to breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). Early detection of BIA-ALCL in patients with implants is crucial for better treatment outcomes.
Area of Science:
- Oncology
- Plastic Surgery
- Medical Device Safety
Background:
- Increasing evidence links breast implants to rare cases of anaplastic large-cell lymphoma (ALCL).
- Breast implant-associated ALCL (BIA-ALCL) is a recognized oncological complication.
Purpose of the Study:
- To review the incidence, clinical presentation, and outcomes of breast implant-associated anaplastic large-cell lymphoma.
- To highlight the importance of differential diagnosis for BIA-ALCL in patients with breast implants.
Main Methods:
- Selective PubMed search for publications from 1997 to January 2018.
- Inclusion of German nationwide database searches.
- Analysis of 516 pathologically confirmed BIA-ALCL cases worldwide.
Main Results:
- 516 BIA-ALCL cases documented globally by February 2018; 7 in Germany.
- BIA-ALCL typically presented as late-onset seroma (80%) or solid tumor.
- Mean implant exposure was 7-13 years; 16 fatalities reported worldwide.
Conclusions:
- The incidence of BIA-ALCL is very low (0.35-1 per million person-years) but higher than other primary breast lymphomas.
- Prompt diagnosis and treatment with curative intent improve prognosis.
- BIA-ALCL must be considered in patients with breast implants presenting with late-developing seroma.
Related Concept Videos
Cleavage and Blastulation
Reproductive Cloning
Somatic Cell Nuclear Transfer
In SCNT, an egg cell is taken from an animal and its nucleus is removed, creating an enucleated egg. Then a somatic...
Bacterial Signaling
In-vitro Mutagenesis

